Artemis Medicare Q2 Revenue Rises 13.2% to Rs 311 Crore

Artemis Medicare Services Ltd reported consolidated revenue of Rs 311 crore for Q2 FY27, a 13.2% year-on-year increase, supported by demand across cardiac sciences, oncology, neurosciences, orthopedics and transplants. The company also reported an adjusted operational EBITDA margin of 23.3%, while its Gurgaon Hospital recorded a 23.8% EBITDA margin.

What did Artemis Medicare report for Q2 FY27?

Artemis Medicare reported higher revenue and operating margins in Q2 FY27, with consolidated revenue from operations reaching Rs 311 crore. Management attributed the year-on-year growth to demand in its key tertiary-care specialties, including cardiac sciences, oncology, neurosciences, orthopedics and transplant services.

The company disclosed an adjusted operational EBITDA margin of 23.3% for the quarter. For the first half of FY27, adjusted EBITDA margin stood at 22.4%. These figures indicate that the company maintained operating profitability while continuing to invest in its hospital network and capacity plans.

How did the Gurgaon Hospital perform during the quarter?

The Gurgaon Hospital achieved its highest reported EBITDA margin of 23.8% in Q2 FY27, with occupancy at 68%. The facility remains central to Artemis Medicare's current operations, and its performance was supported by demand for specialised treatment and the hospital's existing service mix.

Management said it sees scope to take occupancy at the Gurgaon Hospital to 75% while maintaining a similar cost structure. This assessment is based on the hospital's current operating base and implies that additional utilisation could support operating leverage. The company did not provide a timeframe for reaching that occupancy level.

What are Artemis Medicare's planned capacity additions?

Artemis Medicare plans to add 250 beds through Tower 4 in Gurugram by the second half of FY28. The company has also outlined a hospital project in South Delhi with more than 650 beds, which is expected to begin operations in Q4 FY29 or FY30.

The company said it is targeting total capacity of about 2,000 beds over the next three to five years. Its stated geographic focus remains Delhi NCR and the capitals of tier-two cities, primarily in Central and Eastern India. Management said this approach follows market surveys covering insurance penetration and the capacity to pay for tertiary care.

Why are occupancy and specialty demand important for Artemis Medicare?

Occupancy is an important operating measure for hospitals because a larger share of fixed infrastructure costs can be absorbed as more beds and clinical services are used. Artemis Medicare's disclosure that Gurgaon operates at 68% occupancy provides context for management's statement that further utilisation may support margins with a similar cost base.

The revenue growth was linked to specialties that typically require advanced clinical infrastructure and specialist teams. Cardiac sciences, oncology, neurosciences, orthopedics and transplants were specifically identified by the company as growth drivers. The disclosure does not provide a revenue break-up by specialty, but it shows the areas shaping the quarter's demand mix.

What does the expansion plan mean for investors and hospital operations?

The planned Tower 4 and South Delhi projects would materially increase Artemis Medicare's bed base if completed according to the indicated schedule. The near-term project is Tower 4 in Gurugram, with 250 beds expected by H2 FY28, while the South Delhi hospital has a later expected commencement window of Q4 FY29 or FY30.

For investors, the Q2 update combines current operating performance with a multi-year expansion programme. The reported 23.3% adjusted operational EBITDA margin and 13.2% revenue growth provide the current financial reference points, while the execution of new projects, occupancy progression and the stated regional strategy remain relevant operational factors.

Conclusion

Artemis Medicare delivered Q2 FY27 consolidated revenue of Rs 311 crore, up 13.2% year-on-year, alongside a 23.3% adjusted operational EBITDA margin. The Gurgaon Hospital's 23.8% EBITDA margin and 68% occupancy were the key operating indicators disclosed during the update.

The next disclosed milestones are the addition of 250 beds at Tower 4 by H2 FY28 and the expected commencement of the more than 650-bed South Delhi hospital in Q4 FY29 or FY30. Investors will also track progress toward the company's stated target of about 2,000 beds over three to five years.